Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAISSANCE: Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction
NCT06184750Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2024
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Response at any time point at 18 months. Started Sep 2024; status: recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06184750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184750.